Get the Stockscreener App
8.79
1.03%
0.09
Iovance Biotherapeutics Inc stock is traded at $8.79, with a volume of 8.05M.
It is up +1.03% in the last 24 hours and up +101.61% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
See More
Previous Close:
$8.70
Open:
$8.74
24h Volume:
8.05M
Relative Volume:
0.49
Market Cap:
$3.98B
Revenue:
$285.55M
Net Income/Loss:
$-353.86M
P/E Ratio:
-9.2517
EPS:
-0.9501
Net Cash Flow:
$-305.02M
1W Performance:
+9.74%
1M Performance:
+101.61%
6M Performance:
+106.34%
1Y Performance:
+299.55%
1-Day Range:
$8.635
$8.90
1-Week Range:
$7.66
$8.90
52-Week Range:
$1.76
$9.36
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
8.79 | 4.07B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Upgrade | Citizens | Mkt Perform → Mkt Outperform |
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Biotech company Iovance grants 20 new employees options with an $8.99 exercise price - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8%Here's Why - MarketBeat
IOVA Stock Pulls Back As Biotech Momentum Cools - StocksToTrade
UBS Lifts Iovance Biotherapeutics Price Target as Cancer Drug Sales Top Expectations - TIKR.com
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On? - Benzinga
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - TradingView
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance Biotherapeutics grants inducement stock options to 27 new employees - scanx.trade
IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits
Iovance Shares Rise 12.5% as Analyst Price Targets Lag Behind Rally - TechStock²
Iovance Biotherapeutics Q2 results: Revenue beats estimates, stock hits 52-week high - scanx.trade
Why Iovance Biotherapeutics Stock Hit 52-Week High - TradingView
IOVA Maintained by UBS -- Price Target Raised to $7.00 - GuruFocus
Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says - marketscreener.com
META_TITLE_QUOTE - Yahoo Finance
Iovance Biotherapeutics, Inc. (IOVA) Latest Stock News & Headlines - Yahoo Finance
IOVA Stock Jumps As Amtagvi Revenue Beat Fuels Bullish Targets - timothysykes.com
Iovance Biotherapeutics (NASDAQ:IOVA) Marks Major Market Shift - Kalkine Media
Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy - Yahoo Finance
Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates (IOVA) - Seeking Alpha
UBS raises Iovance Biotherapeutics stock price target on revenue beat By Investing.com - Investing.com Canada
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month HighWhat's Next? - MarketBeat
IOVA Stock Hits New 52-Week High As Shares Jump 14% — What Drove The Rally? - TradingView
Iovance Biotherapeutics Rallies as Strong Amtagvi Sales Keep Post-Earnings Momentum Alive - Moomoo
Iovance Biotherapeutics, Inc., Qingdao Sino-Cell Biomedicine Co., Ltd., Grit Biotechnologies, Shanghai Juncell Therapeutics, Curacell Holding Ab, Ksq Therapeutics, Sapphire Biotech, Beijing Sali Biopharmaceutical Co., Ltd. Provide Updates on Til Therapy C - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
TIL Therapy Clinical Trial Pipeline Appears Robust With 17+ - GlobeNewswire
IOVA Stock Climbs As Amtagvi Sales Crush Q2 Expectations - timothysykes.com
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 11% Following Analyst Upgrade - MarketBeat
Iovance (IOVA) Market: Closes 8.25% Higher at $7.61 for the Current Session; Chart View: the Near-Term Reference Band Stretches From $7.23 to $7.99 on the DayGamma Squeeze - Vinanet
Iovance Biotherapeutics (IOVA) Earnings Put Its Valuation Back In Focus - Sahm
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? - Yahoo Finance
IOVA Maintained by Mizuho -- Price Target Raised to $11.00 - GuruFocus
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $11.00 Price Target at Mizuho - MarketBeat
Rice Hall James & Associates LLC Acquires Shares of 1,539,840 Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Mizuho Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $11 - Moomoo
IOVA Stock Price, Quote & Chart - ChartMill
Iovance Biotherapeutics Inc : Baird Assumes C - Moomoo
GSA Capital Partners LLP Buys New Holdings in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Bank of America Corp DE Sells 5,787,694 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026 - The Cryptonomist
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance? - Yahoo Finance
Iovance (IOVA) Q2 2026 Earnings Call Transcript - AOL.com
IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart - ChartMill
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month HighHere's What Happened - MarketBeat
Iovance Biotherapeutics stock hits 52-week high at 6.94 USD By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics (IOVA) Surges 7% as Biotech Sentiment StrengthensBuyback Factor - Vinanet
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iovance Biotherapeutics Inc Stock (IOVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer |
Sep 01 '26 |
Option Exercise |
0.00 |
5,470 |
0 |
253,584 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 01 '26 |
Option Exercise |
0.00 |
8,789 |
0 |
142,709 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Aug 10 '26 |
Option Exercise |
0.00 |
10,001 |
0 |
156,947 |
| Roche Corleen M. | Chief Financial Officer |
Aug 06 '26 |
Option Exercise |
0.00 |
49,995 |
0 |
49,995 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 05 '26 |
Option Exercise |
0.00 |
15,625 |
0 |
569,130 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
144,087 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
9,766 |
0 |
251,957 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
137,896 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 01 '26 |
Option Exercise |
0.00 |
41,668 |
0 |
571,206 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 01 '26 |
Option Exercise |
0.00 |
5,469 |
0 |
244,699 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):